Читать книгу Practical Cardiovascular Medicine - Elias B. Hanna - Страница 169

1 101. Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003; 41: 1273–9.

2 102. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36 (3 Suppl A): 1063–70.

3 103. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117: 686–97.

4 104 Yehudai L, Reynolds HR, Schwarz SA, et al. Serial echocardiograms in patients with cardiogenic shock: analysis of the SHOCK Trial. J Am Coll Cardiol 2006; 47 (suppl A): 111A.

5 105. Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, Hochman JS. Systemic inflammatory response syndrome after acute myocardial infarc- tion complicated by cardiogenic shock. Arch Intern Med 2005; 165: 1643–50.

6 106. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511–15.

7 107. Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, Califf RM, Holmes DR. Long-term outcome and its predictors among patients with ST- elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol 2007; 50: 1752–8.

8 108. French JK, Feldman HA, Assmann SF, et al. Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on 12-month survival in the SHOCK trial. Am Heart J 2003; 146: 804–10.

9 109. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36: 1123–9.

10 110. White HD, Assmann SF, Sanborn TA, at al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the SHOCK trial. Circulation 2005; 112: 1992–2001.

11 111. Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011; 306: 1329–1337. Trend towards lower mortality with IABP at 6 months (1.9% vs 5.2%, p = 0.12) and significant reduction in death/shock/HF. IABP was placed before PCI. A substudy showed improvement of survival in the small subgroup of patients with severe baseline ST elevation≥15 mm in total and persistent ischemia/ST elevation. Another study, PAMI II trial, showed a lack of benefit of IABP in STEMI with HF but no shock.

12 112. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287–96.

13 113. Dhruva SS, Ross JS, Mortazavi BJ, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2020;e200254.

14 114. Amin AP, Spertus JA, Curtis JP, et al. The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. 2020; 141:273–284.

15 115. Schrage B, Ibrahim K, Loehn T, et al. Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation. 2019; 139(10):1249–1258.